The Need for Regulation of Dietary Supplements - Lessons from Ephedra

JAMA

Volumn 289, Issue 12, 2003, Pages 1568-1570

  Fontanarosa, Phil B ^a   Rennie, Drummond ^a   DeAngelis, Catherine D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPHEDRA EXTRACT; EPHEDRINE; FOOD ADDITIVE; PLANT MEDICINAL PRODUCT;

ADVERTIZING; DIET SUPPLEMENTATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; FOOD CONTROL; FOOD SAFETY; LAW; MARKETING; PRIORITY JOURNAL; PUBLIC HEALTH; DRUG APPROVAL; DRUG LEGISLATION; EPHEDRA; HUMAN; NOTE; STANDARD; UNITED STATES;

ADVERTISING; DIETARY SUPPLEMENTS; DRUG APPROVAL; EPHEDRA; EPHEDRINE; HUMANS; LEGISLATION, DRUG; PLANT PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037467294     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.12.1568     Document Type: Editorial

References (14)

1. US Food and Drug Administration. Overview of dietary supplements. Available at: http://www.cfsan.fda.gov/~dms/ds-oview.html. Accessibility verified March 5, 2003.
2. Dietary Supplement Health and Education Act of 1994, Pub L No. 103.417.
3. US Food and Drug Administration White Paper on Ephedra. Evidence on the safety and effectiveness of ephedra: implications for regulation. Available at: http: //www.fda.gov/bbs/topics/NEWS/ephedra/whitepaper.html. Accessibility verified March 5, 2003.
4. Federal Trade Commission. Dietary supplements: an advertising guide for industry. Available at: http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp .htm. Accessibility Verified March 5, 2003.
5. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003; 289:1537-1545.
6. Shekelle PG, Morton S, Maglione M, et al. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. Evidence Report/Technology Assessment No. 76 (Prepared by Southern California Evidence-based Practice Center, RAND, under Contract No. 290-97-0001, Task Order No. 9). AHRQ Publication 03-E022. Rockville, Md: Agency for Healthcare Research and Quality; February 2003.
7. US Food and Drug Administration. HHS acts reduce potential risks of dietary supplements containing ephedra. February 28, 2003. Available at: http://www .fda.gov/bbs/topics/NEWS/2003/NEW00875.html. Accessibility verified March 5, 2003.
8. Haller CA, Benowitz NL. Adverse cardiovascular events and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833-1838.
9. Veltri RW, Marks LS, Miller MC, et al. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. Urology. 2002;60:617-622.
10. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med. 2002;136:590-595.
11. Hoffman B. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the Pharmacologic Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001.
12. Office of Inspector General, Department of Health and Human Services. Adverse event reporting for dietary supplements: an inadequate safety valve. April 2001. Available at: http://oig.hhs.gov/oei/reports/oei-01-00-00180.pdf. Accessibility verified March 5, 2003.
13. Lewis JD, Strom BL. Balancing safety of dietary supplements with the free market. Ann Intern Med. 2002;136:616-618.
14. Bent S, Tiedt TN, Odden MC, et al. The relative safety of ephedra compared with other herbal products. Ann Intern Med. 2003. Available at: http://www.acponline.org/journals/annals/ephedra.htm?hp. Accessibility verified March 5, 2003.